ALVEOLAR RHABDOMYOSARCOMA TREATMENT MARKET ANALYSIS

Alveolar Rhabdomyosarcoma Treatment MarketSize and Trends

Alveolar Rhabdomyosarcoma Treatment Market: Market Dynamics

Rising incidence of alveolar rhabdomyosarcoma along with technological advancements in radiation therapy is expected to augment market growth of alveolar rhabdomyosarcoma treatment. According to the survey by the University of Minnesota, 2014, soft tissue sarcomas (STS) comprises about 7% of all malignancies in children and adolescents under the age of 20 years and rhabdomyosarcoma (RMS) accounts for about 40% of pediatric STS. The incidence of RMS is 4.5 cases/million children/adolescents per year, where ARMS comprises 31% of RMS and in 50% cases the condition is highly prevalent below the age of 10. Also, latest advancements in radiation therapy, which are largely adopted by major hospitals such as Mayo Clinic, Memorial Sloan Kettering Cancer Center include proton beam therapy program that provides highly targeted precision beams to destroy cancerous cells by sparing the healthy surrounding tissues.

Moreover, various government and non-government organizations are undertaking research initiatives to improve the outcomes of alveolar rhabdomyosarcoma as the condition is associated with lower survival rates. Several clinical trials are conducted by large international cooperative groups, such as Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) and the National Comprehensive Cancer Network (NCCN) to provide innovative treatments based on latest research, which in turn is expected to bolster market growth in the forecast period. Also, researchers at Oregon Health & Science University Doernbecher Children's Hospital have identified a promising new approach to overcoming drug resistance and increase the survival rate in children with alveolar rhabdomyosarcoma. According to the Oregaon Health and Science University, 2011, the survival rate among alveolar rhabdomyosarcoma patients after extensive therapy is less than 20%.

Organizations and manufacturers are conducting clinical trials to investigate novel therapies to treat pediatric cancers. For instance, in 2015, Novartis Pharmaceuticals initiated the Phase 1 study for Trametinib in combination with Dabrafenib in children and adolescents with alveolar rhabdomyosarcoma harboring V600 mutations.

Alveolar Rhabdomyosarcoma Treatment Market: Market Taxonomy

On the basis of therapy type, the global alveolar rhabdomyosarcoma treatment market is segmented into:

• Chemotherapy
• Radiation Therapy
• Combination Therapy

On the basis of end user, the global alveolar rhabdomyosarcoma treatment market is segmented into:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers